Ruxolitinib for Hemophagocytic Lymphohistiocytosis

(RISE Trial)

This trial tests ruxolitinib, a medication that may help treat Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). This condition can occur after patients receive CAR-T therapy, a specific type of cancer treatment. Researchers aim to determine if ruxolitinib is safe and effective for these patients, studying the duration of treatment and its effects on the body. This trial may suit individuals diagnosed with IEC-HS after CAR-T therapy who experience symptoms like high fevers, breathing trouble, or liver issues. Participants must be able to take medication orally or be willing to use a feeding tube if necessary. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this potentially groundbreaking therapy.

Research has shown that ruxolitinib is generally safe and well-tolerated for people with hemophagocytic lymphohistiocytosis (HLH). In past studies, ruxolitinib demonstrated good safety results in both adults and children with HLH. Reports suggest that patients can take it at home, eliminating the need for hospital stays, which makes it a convenient choice for many.

Ruxolitinib is unique because it targets a different pathway than most traditional treatments for hemophagocytic lymphohistiocytosis (HLH), which often rely on immunosuppressive therapies like corticosteroids or chemotherapy. This drug specifically inhibits the JAK1 and JAK2 enzymes, which play a crucial role in the inflammatory process of HLH. Researchers are excited about ruxolitinib because it offers a more targeted approach, potentially leading to fewer side effects and more effective management of the condition. Additionally, its ability to be tailored based on platelet counts may allow for personalized dosing, improving patient outcomes.

Research has shown that ruxolitinib can help treat hemophagocytic lymphohistiocytosis (HLH), a serious immune system disorder. One study found that 76% of patients who took ruxolitinib survived. Another study discovered that combining ruxolitinib with a milder treatment plan maintained its benefits while reducing side effects. In this trial, patients will receive ruxolitinib at varying doses based on their platelet levels. Specifically, patients taking ruxolitinib experienced better symptom relief after dose adjustments. These findings suggest that ruxolitinib may help manage conditions like IEC-HS, especially following CAR-T therapy.¹²³⁵⁶